We have built on our simultaneous metagenomic deep-sequencing and targeted amplicon sequencing platform, SmartBiome™, to create SmartBiome ID™.
SmartBiome ID is a broad spectrum clinical test that detects and identifies a wide range of microorganisms from a single sample of a variety of types, including blood, stool, and urine, among others.
Although metagenomic deep-sequencing is already used as a way to identify novel functional genes, microbial pathways, antibiotic resistance, and genes that are involved in the process of interactions between microbiome and host, its largest limitation to date has been its relatively limited ability to resolve low abundance species or genes. SmartBiome ID overcomes this limitation by combining targeted sequencing of a variety of genes with metagenomic sequencing, in an approach we call precision sequencing™.
SmartBiome ID use of precision sequencing™ allows it to generate precise information at a high resolution, enabling a distinction to be made between strains of pathogens that differ by as little as one single-nucleotide polymorphism (SNP).
uBiome is currently seeking hospitals, physicians, and other partners to pilot SmartBiome ID in the clinical setting.
To apply, please complete the form below. Our clinical team will review your information and follow up with additional information on the SmartBiome ID pilot program. If you have any questions, please contact smartbiomeID@ubiome.com.